Significance Statement {#s1}
======================

GABA neurotransmission is mediated primarily by GABA~A~ receptors (GABA~A~Rs). These receptors are composed of different combinations of five subunits that determine their pharmacological properties and subcellular location. Differences in the expression of GABA~A~Rs that contain the γ2 subunit versus those that contain the δ subunit may regulate the balance between synaptic and extrasynaptic GABA neurotransmission. We report here that expression of the γ2 and the δ subunits are differentially regulated within the circadian pacemaker in the suprachiasmatic nucleus (SCN) and provide evidence that the balance between synaptic and extrasynaptic GABA~A~Rs determine the functional response to GABA and that this balance is regulated in a site-specific manner within the SCN.

Introduction {#s2}
============

GABA, the primary inhibitory neurotransmitter in the brain, plays a key role in regulating the firing patterns of individual neurons and entire neural networks ([@B21]). GABA~A~ receptors (GABA~A~Rs) are pentameric chloride channels comprised of three different proteins from 19 available subunits and are generally composed of two α, two β, and one γ, δ, or ε subunit ([@B49]; [@B54]; [@B21]). Subunit composition determines their anatomic location and physiologic properties ([@B21]).

α4, α5, α6, and δ subunits are found at peri- and extrasynaptic locations, whereas α1 and γ2 are found within the synapse ([@B20]). γ2 and δ subunits are mutually exclusive in receptor complexes ([@B3]) and have different properties. δ GABA~A~Rs display tonic chloride conductance, do not readily desensitize, and are referred to as GABA~A~-TONIC receptors ([@B56]; [@B2]). γ2 GABA~A~Rs form perisynaptic clusters that then move into the synapse ([@B17]; [@B12]), where they modulate fast (phasic) conductance, rapidly desensitize following activation, have 50-fold lower GABA affinity, and are referred to as GABA~A~-PHASIC receptors ([@B56]; [@B2]). Although much is known about the diversity of GABA~A~Rs, little is known about their transcriptional regulation ([@B21]) and even less about their specific roles in coregulating GABA networks.

The SCN in the anterior hypothalamus is the central circadian pacemaker that entrains an organism's physiology and behavior to environmental light-dark (LD) cycles ([@B57]). The SCN provides the opportunity to study the network properties of GABA, because it contains a robust local GABA network with distinct inputs (e.g., light) and easily measured outputs (e.g., phase shift in circadian rhythms). Given that all or nearly all neurons within the SCN produce GABA as a neurotransmitter, it is likely that GABA has a fundamental role in circadian timekeeping ([@B59]; [@B38]; [@B8]; [@B2]). Indeed, GABA plays a major role in the ability of the circadian pacemaker to be reset by environmental stimuli. Muscimol, an agonist which activates GABA~A~Rs that contain either the γ2 or the δ subunit, injected into the SCN phase advances the circadian pacemaker during subjective day ([@B55]; [@B28]; [@B37]; [@B16]; [@B5]), mimicking the effects of nonphotic stimuli (e.g., locomotor activity; [@B44]; [@B43]). Diazepam, a benzodiazepine that acts at γ2 containing receptors similarly phase advances the clock during the subjective day ([@B36]).

GABA~A~Rs are also critical in the phase resetting effects of light. Acute administration of muscimol into the SCN blocks the ability of light to induce phase delays in the early subjective night and phase advances during the late subjective night ([@B23], [@B24]; [@B46]). Acute administration of the nonselective GABA~A~ antagonist bicuculline enhances light-induced phase delays during the early subjective night ([@B23]). More recently, the sustained activation of GABA~A~Rs has been found to be both necessary and sufficient to mediate the phase delaying effects of light during the early subjective night ([@B29]). Taken together, it is clear that GABA~A~Rs play a fundamental role in determining how both light and nonphotic signals influence the phase of the pacemaker found within the SCN.

Despite the importance of GABA~A~Rs in regulating the phase of the circadian pacemaker, the role of GABA~A~Rs composed of different subunits is not well understood. Based on several studies, there is a consensus that α1, α2, β1, β2, and γ2 subunit mRNA or proteins are expressed in the SCN ([@B22]; [@B47]; [@B45]). To our knowledge, only one study has investigated GABA~A~δ in the SCN and reported it undetectable by Western blotting ([@B47]). Pharmacological evidence, however, indicates the presence of and a separate role in entrainment for both δ and γ2 GABA~A~Rs in the SCN ([@B15]; [@B36]). The aim of this study was to investigate how the expression of GABA~A~δ and γ2 subunits varies within the SCN across circadian time (CT) to test the hypothesis that rhythms in GABA~A~-TONIC (δ) and GABA~A~-PHASIC (γ2) receptors and/or their ratio mediate the phase-dependent effects of GABA on the circadian pacemaker.

Materials and Methods {#s3}
=====================

Animals and housing {#s3A}
-------------------

Adult male Syrian hamsters (*Mesocricetus auratus*, 120--150 g) were purchased from Charles River Laboratories. On arrival, hamsters were singly housed in polycarbonate cages (23 × 43 × 20 cm) with corncob bedding, given ad libitum access to food (\#5001; Lab Diet) and water, and maintained in 14:10 light:dark (LD) cycle for 7--10 d before any manipulation. The Department of Animal Resources at Georgia State University provided all animal husbandry. All procedures were approved by the Georgia State University Institutional Animal Care and Use Committee and were in compliance with guidelines established by the National Institutes of Health \[[@B30]\] and established by the Society for Neuroscience.

Experiment 1: Effects of GABA~A~R subtype-specific agonists on phase resetting {#s3B}
------------------------------------------------------------------------------

Under isoflurane anesthesia, hamsters were stereotaxically implanted with a 26-ga guide cannula (PlasticsOne) aimed at the SCN region (AP +0.7 mm; ML +1.7 mm; 10° angle toward midline). Cannulae were anchored to the skull with bone screws and cranioplastic cement. Hamsters recovered a minimum of 7 d in LD, and were then given access to a running wheel (33 cm diameter; Techniplast) and placed in constant darkness (0:24 light:dark; DD). Running wheel activity rhythms were recorded remotely using VitalView software (Starr Life Sciences) and phase shifts in activity onsets were quantified using the linear regression method ([@B52]) and ClockLab software (Actimetrics). By convention, for nocturnal animals CT12 was defined as the time of activity onset. After a minimum of 10 d in DD, microinjections (200 nl, administered over a 20 s period) were given under dim red light with a 1.0-μl Hamilton syringe connected to a 33-ga needle that projected to a final depth of 7.8 mm below bregma. The needle remained in place for 20 s after the injection. The GABA~A~δ superagonist 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) and the nonselective GABA~A~ agonist muscimol, purchased from Sigma, were dissolved in sterile 0.9% saline at concentrations of 110 and 11 mM, respectively ([@B15]; [@B29]), immediately before injections. Although THIP is a superagonist at extrasynaptic (δ) receptors, it is only a partial agonist at synaptic (γ2) receptors at high concentrations ([@B27]). Furthermore, THIP has very low affinity for native intrasynaptic γ2 receptors ([@B14]), thus it is likely only affecting extrasynaptic GABA~A~δ receptors *in vivo*. For injections at CT6, hamsters were returned to their home cage in DD immediately after the injection. Injections at CT13.5 or CT19 were immediately followed by a 15-min 150 lux light pulse after which hamsters were returned to their home cages in DD. Hamsters with stable rhythms received an additional microinjection 10--14 d following the first treatment (to allow for stable reestablishment of the free-running rhythm) and were returned to running wheels in DD for another 10--14 d. No hamster received more than two injections. At the conclusion of testing, hamsters were killed by sodium pentobarbital overdose and then injected with ink to verify cannula placement. After histologic examination, hamsters with injection sites found to surround (within 500 μm), but not damage the SCN, were included in the analyses. It has been previously shown that drugs injected 500 μm or further from the SCN border do not phase shift the circadian pacemaker ([@B29]) and that injections in a volume of 200 nl (the volume used in the present study) spread slightly less than a mm from the tip of the injection needle ([@B1]; [@B7]). The hamster SCN is ∼0.6 mm in the rostral-caudal plane, ∼0.3 mm in the mediolateral plane, and ∼0.6 mm in the dorso-ventral plane ([@B35]). Because the hamster SCN lies ventral and not lateral to the third ventricle, and the SCN actually merge bilaterally midway along the dorsoventral axis, there is little barrier to the spread of drugs bilaterally. Indeed, it has been shown that injections using a volume of 200 nl diffuse bilaterally throughout the SCN ([@B25]; [@B50]). Taken together, these data suggest that injections within 500 μm of the SCN should diffuse throughout the bilateral SCN and for a short distance outside the borders of the nucleus.

Experiment 2: GABA~A~R subunit gene expression in the SCN {#s3C}
---------------------------------------------------------

After habituation to the animal facility, hamsters either remained in LD or were placed in DD and given access to running wheels as described in experiment 1 above. After 10 additional days in either LD or DD, hamsters were given a lethal overdose of sodium pentobarbital, decapitated, and brains were rapidly removed and placed in 2.5 ml of RNAlater (Ambion) then held at 4°C for one to two weeks before RNA extraction. Brains were collected at zeitgeber time (ZT)6, ZT13, and ZT19 from hamsters in LD, and at CT6, CT13, and CT19 from hamsters in DD. By convention for nocturnal animals ZT12 is the onset of activity, thus in the 14:10 LD cycle lights on occurred at ZT22 and lights off at ZT12. For ZT13, ZT19, and all DD time points, brains were collected under dim red light (\<5 lux). After RNA stabilization in RNAlater, brains were then placed in a matrix and a 1.0 mm thick slice containing the SCN was collected onto a glass slide. SCN were then collected into 200 μl of Trizol (Ambion) using a 1.0-mm tissue punch. Individual SCN were homogenized in 1.0 ml Trizol using a sterile pestle and RNA was extracted following manufacturer's protocol. RNA was washed twice with chloroform and precipitated with 100% isopropanol. The pellet was then washed twice with 75% ethanol, resuspended in 20 μl of water, and RNA concentration was determined using a NanoDrop 2000. Following extraction, 150 ng of total RNA was then reverse transcribed into cDNA using M-MLV (Promega) following the manufacturer's protocol. Relative gene expression was quantified using an ABI 7500 FAST Real-Time system using Taqman Universal PCR master mix and the following universal two-step RT-PCR cycling conditions: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The following primer/probe sets from Applied Biosystems were used: GABA~A~δ (ABI Mm01266203_g1), GABA~A~γ2 (ABI Rn00788325_m1), and 18s (4319413E). Relative gene expression for each sample run in duplicate was calculated by comparing to a relative standard curve and then standardized to 18S rRNA expression. Relative cDNA standards were generated using pooled hippocampal RNA extracts, which included tissue from animals at each CT point.

Experiment 3: GABA~A~R subunit protein expression in the SCN {#s3D}
------------------------------------------------------------

Hamsters were housed as described in experiment 2 above. At the same circadian and zeitgeber time points as described in experiment 2, hamsters were given a lethal overdose of sodium pentobarbital, followed by a transcardial perfusion with 100 ml of ice cold 0.1 M PBS, pH 7.4, then followed by 100 ml of freshly made ice cold 4% paraformaldehyde in 0.1 M PBS. Brains were removed and postfixed in 4% paraformaldehyde 0.1 M PBS at 4°C. After 12--16 h of postfixation, brains were placed in 0.1 M PB + 30% sucrose at 4°C. Once brains had sunk in the sucrose solution, they were then flash frozen in 2-methylbutane on dry ice, and held at −80°C until sectioning. Brains were sectioned at 40 μm on a cryostat, and three sets of serial coronal sections containing the SCN were collected into cryoprotectant and held at −20°C for immunohistochemical staining. A representative series of sections from each brain was then processed for either GABA~A~δ (Millipore catalog AB9752, RRID:AB_672966) or GABA~A~γ2 (Abcam catalog ab16213, RRID:AB_302324). Briefly, free floating tissue sections were rinsed three times in 0.1 M PBS + 0.1% Triton X-100 (PBST), blocked in 10% normal goat serum (NGS) in PBST for 30 min, and incubated in primary antibody (1:250 in PBST + 10% NGS) overnight at 4°C. Sections were then rinsed in PBST and incubated in secondary antibody (Jackson ImmunoResearch 111-065-003; 1:500 in PBS + 5% NGS) for 2 h at room temperature. After secondary incubation, tissue was rinsed in PBS, complexed with ABC (Avidin/Biotinylated enzyme Complex, Vector PK-6100), and developed with nickel 3,3'-diaminobenzidine (Ni-DAB; Vector SK-4100) according to the manufacturer's protocols. Sections were then mounted onto chrome-gel subbed slides, dried, dehydrated in a graded ethanol series, cleared with xylenes, and coverslipped with Permount (Fisher). Immunohiostochemistry was yoked so that all tissue sections for each protein of interest were processed simultaneously allowing for direct comparisons of relative protein levels among groups.

Digital monochrome images were captured at 100× using a Zeiss Axioplan2 microscope fitted with a ProgRes SpeedXT core5 camera (JENOPTOK). All images used for protein quantification were taken in a single session without altering microscope or camera settings. For each representative series of brain sections, four images were captured representing the rostral, central anterior, central posterior, and caudal SCN as previously described in hamsters ([@B34]; [@B26]). These regions correspond to those found in figures 23--25 of the golden hamster brain atlas ([@B42]). Using ImageJ, a region of interest (ROI) was defined that included the entire unilateral SCN. This ROI was then used to measure grayscale values of the SCN in each image. The grayscale value corresponds to the optical density of the DAB staining and thus is a measure of relative protein expression. Grayscale values were then inverted (255, measured value), so that higher numbers were indicative of relatively more protein-IR. Given that there is ongoing controversy about the functional neuroanatomical subdivisions of the SCN (reviewed in [@B39]; [@B33]; [@B41]; [@B40]; [@B18]; [@B19]; [@B2]), and that GABA~A~ subunit distribution has been reported to vary across the rostro-caudal and dorso-ventral extent of the SCN ([@B22]; [@B4]), we measured and analyzed protein expression in several different ways. First we analyzed the whole SCN by averaging the grayscale values of each ROI across the rostral-caudal extent, resulting in a single value for each whole SCN. Next, for a dorsal versus ventral anatomic division of the SCN, the initial ROI was further divided in half on the dorsal-ventral axis, and grayscale values were measured for each image and then averaged across the rostro-caudal extent of each SCN as described above, resulting in one dorsal and one ventral grayscale value. Finally, grayscale values were collected for each individual sub-ROI, resulting in eight grayscale values for each SCN (dorsal and ventral × four rostro-caudal divisions). All measurements were made by an observer blind to the experimental condition of the hamster.

Based on studies using genetic techniques in mice, GABA~A~ γ2 and δ appear to reciprocally regulate each other's expression independent of receptor activity ([@B31]; [@B60]). Thus, we also compared the relative protein-IR levels for the two GABA~A~R subtypes by comparing the relationship of their relative ratios (δ-IR:γ2-IR) across time points and lighting conditions. Although this ratio does not represent a direct measure of the absolute amounts of protein within the SCN, it does represent the relative change in the amounts of these proteins in relation to each other.

Statistics {#s3E}
----------

All statistical analyses were performed using SPSS 22.0 (IBM). Pharmacological data (experiment 1) were analyzed using one-way ANOVA (analysis of variance) with phase shift as the dependent variable and drug treatment as the independent variable. Significant ANOVAs were followed up with a Fisher's LSD *post hoc* test. For experiment 2, gene expression data were also analyzed by one-way ANOVA with relative expression or expression ratio as the dependent variable and zeitgeber time or circadian time as independent variables. Significant ANOVAs were followed up with a Fisher's LSD *post hoc* test. Gene expression data were also analyzed by independent samples *t* test with circadian phase as the independent variable. Protein-IR data were first analyzed using one-way ANOVA and independent samples *t* test as described above. To ascertain the anatomic location in the SCN of interactions between light regimen and circadian phase, protein-IR data were then analyzed by SCN anatomic subdivision using 2 × 2 MANOVA (multivariate analysis of variance) with grayscale value or expression ratio as the dependent variable and circadian phase and lighting condition as independent variables. To ascertain the effects of environmental lighting condition on GABA~A~ protein-IR, data were analyzed using an independent samples *t* test with lighting regimen (LD vs DD) as the independent variable. Finally, to ascertain the differences in GABA~A~ protein-IR between the dorsal and ventral SCN, a different independent samples *t* test was performed using these two factors as the independent variables. Differences were considered statistically significant at *p* ≤ 0.05. The numbers of animals used in each experiment are listed in [Table 7](#T7){ref-type="table"}.

Results {#s4}
=======

Experiment 1: Phase shifting effects of GABA~A~ agonists {#s4A}
--------------------------------------------------------

During the subjective day (CT6), the GABA~A~γ2/GABA~A~δ agonist muscimol induced a phase advance in circadian wheel running activity, whereas neither saline or the GABA~A~δ superagonist THIP had any effect on circadian phase (*F*~(2,21)~ = 8.544, *p* ≤ 0.05; [Fig. 1*A*](#F1){ref-type="fig"}). During the subjective night, both THIP and muscimol blocked the phase delaying (CT13.5, *F*~(4,16)~ = 16.438, *p* ≤ 0.05; [Fig. 1*B*](#F1){ref-type="fig"}) and phase advancing (CT19, *F*~(4,17)~ = 5.455, *p* ≤ 0.05; [Fig. 1*C*](#F1){ref-type="fig"}) effects of a light pulse when compared with saline ([Fig. 1](#F1){ref-type="fig"}). THIP was more effective than muscimol in blocking a light-induced phase delay during the early subjective night (CT13.5, *p* ≤ 0.05; [Fig. 1*B*](#F1){ref-type="fig"}). However, in the absence of a light pulse at CT13.5, animals treated with THIP showed a small phase delay compared with those treated with muscimol ([Fig. 1*B*](#F1){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Neither muscimol nor THIP had an effect on phase in the absence of a light pulse during the late subjective night (*p* \> 0.05; [Fig. 1*C*](#F1){ref-type="fig"}).

![Extrasynaptic GABA~A~Rs contribute to the acute effects of GABA in the SCN during the subjective night but not during the subjective day. The nonselective GABA~A~-PHASIC/GABA~A~-TONIC agonist muscimol (2.2 nmol) phase advanced the pacemaker at CT6, whereas the GABA~A~-TONIC receptor superagonist THIP (22 nmol) had no effect (***A***). Both agonists were effective in blocking the phase shifting effects of a 15-min 150 lux light pulse during the subjective night (CT13.5 and CT19; ***B***, ***C***, respectively). THIP was more effective than muscimol at blocking photic phase delays at CT13.5 (***B***). In the absence of a light pulse, animals treated with THIP showed a small phase delay compared with those treated with muscimol at CT13.5 (***B***). Neither muscimol nor THIP had an effect on phase in the absence of a light pulse during the late subjective night (***C***). NP, no light pulse; LP, light pulse (150 lux, 15 min), \**p* ≤ 0.05. Statistics for all analyses in [Table 1](#T1){ref-type="table"}.](enu0021723000001){#F1}

###### 

Analysis of GABA~A~ active drugs on phase resetting

  One-way ANOVA                                                                 
  ---------------- ----------------- ------------------------------------------ ------------------------------------------
  CT               *F* statistic     *p* value                                  
  CT6              (2,21) = 8.544    [\*](#TF1){ref-type="table-fn"}**0.002**   
  CT13.5           (4,16) = 16.438   [\*](#TF1){ref-type="table-fn"}**0.000**   
  CT19             (4,17) = 5.455    [\*](#TF1){ref-type="table-fn"}**0.005**   
  LSD *post hoc*                                                                
  CT               Treatment vs      Treatment                                  *p* value
  CT6              SALINE-NP         MUSCIMOL-NP                                [\*](#TF1){ref-type="table-fn"}**0.001**
                                     THIP-NP                                    0.488
                   MUSCIMOL-NP       SALINE-NP                                  [\*](#TF1){ref-type="table-fn"}**0.001**
                                     THIP-NP                                    [\*](#TF1){ref-type="table-fn"}**0.004**
                   THIP-NP           SALINE-NP                                  0.488
                                     MUSCIMOL-NP                                [\*](#TF1){ref-type="table-fn"}**0.004**
  CT13.5           SALINE-LP         MUSCIMOL-LP                                [\*](#TF1){ref-type="table-fn"}**0.000**
                                     THIP-LP                                    [\*](#TF1){ref-type="table-fn"}**0.000**
                                     MUSCIMOL-NP                                [\*](#TF1){ref-type="table-fn"}**0.000**
                                     THIP-NP                                    [\*](#TF1){ref-type="table-fn"}**0.000**
                   MUSCIMOL-LP       SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.000**
                                     THIP-LP                                    [\*](#TF1){ref-type="table-fn"}**0.019**
                                     MUSCIMOL-NP                                [\*](#TF1){ref-type="table-fn"}**0.015**
                                     THIP-NP                                    0.913
                   THIP-LP           SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.000**
                                     MUSCIMOL-LP                                [\*](#TF1){ref-type="table-fn"}**0.019**
                                     MUSCIMOL-NP                                0.696
                                     THIP-NP                                    0.051
                   MUSCIMOL-NP       SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.000**
                                     MUSCIMOL-LP                                [\*](#TF1){ref-type="table-fn"}**0.015**
                                     THIP-LP                                    0.696
                                     THIP-NP                                    [\*](#TF1){ref-type="table-fn"}**0.036**
                   THIP-NP           SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.000**
                                     MUSCIMOL-LP                                0.913
                                     THIP-LP                                    0.051
                                     MUSCIMOL-NP                                [\*](#TF1){ref-type="table-fn"}**0.036**
  CT19             SALINE-LP         MUSCIMOL-LP                                [\*](#TF1){ref-type="table-fn"}**0.003**
                                     THIP-LP                                    [\*](#TF1){ref-type="table-fn"}**0.001**
                                     MUSCIMOL-NP                                [\*](#TF1){ref-type="table-fn"}**0.007**
                                     THIP-NP                                    [\*](#TF1){ref-type="table-fn"}**0.006**
                   MUSCIMOL-LP       SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.003**
                                     THIP-LP                                    0.541
                                     MUSCIMOL-NP                                0.863
                                     THIP-NP                                    0.879
                   THIP-LP           SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.001**
                                     MUSCIMOL-LP                                0.541
                                     MUSCIMOL-NP                                0.459
                                     THIP-NP                                    0.694
                   MUSCIMOL-NP       SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.007**
                                     MUSCIMOL-LP                                0.863
                                     THIP-LP                                    0.459
                                     THIP-NP                                    0.766
                   THIP-NP           SALINE-LP                                  [\*](#TF1){ref-type="table-fn"}**0.006**
                                     MUSCIMOL-LP                                0.879
                                     THIP-LP                                    0.694
                                     MUSCIMOL-NP                                0.766

*p* \< 0.05.

Experiment 2: GABA~A~R subunit gene expression in the SCN {#s4B}
---------------------------------------------------------

When relative mRNA expression was analyzed by one-way ANOVA with time of day as the independent variable, variation in mRNA levels for both subunits did not reach statistical significance in either LD or DD (*p* \> 0.05; [Fig. 2](#F2){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). However, when analyzed using an independent samples *t* test with circadian phase (light vs dark phase in LD; active vs inactive phase in DD) as the independent variable, differences in expression were apparent. The GABA~A~δ receptor subunit mRNA varied by circadian phase (i.e., ZT6 vs ZT13 and ZT19) in SCN dissections from hamsters housed under LD conditions (*t*~(15)~ = 2.498, *p* ≤ 0.05), with the highest expression during the light (inactive) phase ([Fig. 2*A*](#F2){ref-type="fig"}). In contrast, the mRNA encoding the GABA~A~γ2 receptor subunit did not vary between the dark (active) and light (inactive) phases in LD (*t*~(15)~ = −0.979, *p* \> 0.05; [Fig. 2*B*](#F2){ref-type="fig"}). The ratio of the GABA~A~δ receptor subunit mRNA to the GABA~A~γ2 receptor subunit did not vary by circadian phase in LD (*t*~(15)~ = 1.181, *p* \> 0.05; [Fig. 2*C*](#F2){ref-type="fig"}). In hamsters housed in DD, the ratio of GABA~A~δ receptor subunit mRNA to GABA~A~γ2 receptor mRNA varied by circadian phase (i.e., CT6 vs CT13 and CT19) after 10 d in DD (*t*~(14)~ = 2. 317, *p* ≤ 0.05), with the highest ratio of GABA~A~δ-to-GABA~A~γ2 receptor subunit mRNA occurring during the inactive phase ([Fig. 2*F*](#F2){ref-type="fig"}). There were no differences in GABA~A~δ receptor subunit mRNA or in GABA~A~γ2 receptor subunit mRNA in DD due to circadian phase ([Fig. 2*D*,*E*](#F2){ref-type="fig"}).

![Rhythmic GABA~A~R mRNA expression in the SCN. Expression of the extrasynaptic GABA~A~δ receptor mRNA (***A***, ***D***) varied by circadian phase in a 14:10 LD cycle (***A***) with the highest level of expression during the day. Expression of the synaptic GABA~A~γ2 receptor RNA did not significantly vary across the day (***B***, ***E***). The ratio of extrasynaptic-to-synaptic receptor mRNA (δ:γ2) (***C***, ***F***) varied by circadian phase after 10 d in DD conditions (***F***), with the highest relative expression of GABA~A~δ occurring during the inactive phase (subjective day). \**p* ≤ 0.05. Statistics in [Table 2](#T2){ref-type="table"}.](enu0021723000002){#F2}

###### 

Analysis of GABA~A~ mRNA transcript expression

  Condition   Type of test                   Comparison              Gene     *F* statistic    *t* value         *p* value
  ----------- ------------------------------ ----------------------- -------- ---------------- ----------------- ------------------------------------------
  LD          One-way ANOVA                  Zeitgeber time          *δ*      (2,14) = 2.593                     0.085
              One-way ANOVA                  (ZT6 vs ZT13 vs ZT19)   *γ2*     (2,14) = 0.466                     0.637
              One-way ANOVA                                          *δ:γ2*   (2,14) = 0.749                     0.491
              Independent samples *t* test   Zeitgeber phase         *δ*                       \(15\) = 2.498    [\*](#TF2){ref-type="table-fn"}**0.025**
              Independent samples *t* test   (light vs dark)         *γ2*                      \(15\) = −0.979   0.343
              Independent samples *t* test                           *δ:γ2*                    \(15\) = 1.181    0.256
  DD          One-way ANOVA                  Circadian time          *δ*      (2,13) = 2.598                     0.112
              One-way ANOVA                  (CT6 vs CT13 vs CT19)   *γ2*     (2,13) = 0.946                     0.413
              One-way ANOVA                                          *δ:γ2*   (2,13) = 2.677                     0.106
              Independent samples *t* test   Circadian phase         *δ*                       \(14\) = 1.036    0.318
              Independent samples *t* test   (inactive vs active)    *γ2*                      \(14\) = −1.734   0.191
              Independent samples *t* test                           *δ:γ2*                    \(14\) = 2.317    [\*](#TF2){ref-type="table-fn"}**0.036**

*p* \< 0.05.

Experiment 3: GABA~A~R subunit protein-IR in the SCN {#s4C}
----------------------------------------------------

Nickel-enhanced DAB immunohistochemistry revealed diffuse IR for both GABA~A~R subunit proteins throughout the SCN ([Fig. 3](#F3){ref-type="fig"}). This diffuse staining pattern seen in the SCN has been previously reported for multiple GABA~A~R subunits in a variety of brain regions and neuronal cell types ([@B58]; [@B6]; [@B11]; [@B51]). As mentioned in Materials and Methods above, we measured and analyzed protein-IR in the whole SCN as well as in commonly used subdivisions of the SCN to allow the current results to be integrated with data from functional neuroanatomical subdivisions of the SCN that have been discussed previously (reviewed in [@B39]; [@B33]; [@B41]; [@B40]; [@B61]; [@B18]; [@B19]; [@B2]).

![Photomicrographs of GABA~A~R subunit IR in the SCN. Representative photomicrographs of nickel-enhanced DAB immunohistochemical staining for extrasynaptic GABA~A~δ and synaptic GABA~A~γ2 proteins in the retinorecipient region (central posterior) of the SCN across time points and photic housing conditions (***A***). Representative 200× images of GABA~A~δ (***B***) and GABA~A~γ2 (***C***). Scale bars in ***A***, ***C*** = 150 μm.](enu0021723000003){#F3}

First, to allow direct comparison with the analyses of mRNA expression data in experiment 2, we performed a quantitative analysis of protein-IR of the whole SCN by one-way ANOVA with protein-IR as the dependent variable and zeitgeber time (LD) or circadian time (DD) as independent variables. We also analyzed whole SCN protein-IR using an independent samples *t* test with circadian phase (light vs dark phase in LD; active vs inactive phase in DD) as the independent variable as in experiment 2 above. Combining the two night time measurements and directly comparing them to the day time represents a functional grouping based on the effects of GABA~A~-active drugs across the circadian cycle as described above ([@B55]; [@B28]; [@B23]; [@B24]; [@B25]; [@B37]; [@B46]; [@B16]; [@B5]). The results of both analyses are found in [Table 3](#T3){ref-type="table"}. The intensity of GABA~A~δ protein-IR did not vary across time points in hamsters housed in LD (i.e., ZT6 vs ZT13 vs ZT19; [Fig. 4*A*](#F4){ref-type="fig"}) or in hamsters housed in DD (i.e., CT6 vs CT13 vs CT19; [Fig. 4*D*](#F4){ref-type="fig"}), nor by phase in hamsters housed in DD (i.e., CT6 vs CT13 and CT19; [Fig. 4*D*](#F4){ref-type="fig"}). There was, however, a trend for greater GABA~A~δ protein-IR in the dark (active) phase in hamsters housed in a LD cycle (*p* = 0.06; [Fig. 4*A*](#F4){ref-type="fig"}). GABA~A~γ2 protein-IR varied by time point and by phase in hamsters housed in a LD cycle; protein-IR was at nadir during the day and peak levels occurred at night, with the highest levels in the early night (*p* ≤ 0.05; [Fig. 4*B*](#F4){ref-type="fig"}). After free-running in DD for 10 d, a circadian rhythm in GABA~A~γ2 protein-IR in the SCN was observed, with significantly higher levels occurring during the subjective day (CT6) than during the subjective night (CT13 and CT19, *p* ≤ 0.05; [Fig. 4*E*](#F4){ref-type="fig"}). Based on studies using genetic techniques in mice, GABA~A~ γ2 and δ appear to reciprocally regulate each other's expression and insertion into the cell membrane, independent of receptor activity ([@B31]; [@B60]). Although it was not possible to measure membrane bound subunits, we analyzed the relative ratio of GABA~A~δ:GABA~A~γ2 protein-IR as a measure of how the relative amounts of these two proteins vary in relation to each other across the day. The ratio of extrasynaptic:synaptic subunit protein-IR did not vary in the whole SCN in LD or DD (*p* \> 0.05; [Fig. 4*C*,*F*](#F4){ref-type="fig"}).

###### 

Analysis of GABA~A~R protein-IR

  Condition   Type of test                   Comparison              Protein   *F* statistic    *t* value         *p* value
  ----------- ------------------------------ ----------------------- --------- ---------------- ----------------- ------------------------------------------
  LD          One-way ANOVA                  Zeitgeber time          *δ*       (2,9) = 2.271                      0.159
              One-way ANOVA                  (ZT6 vs ZT13 vs ZT19)   *γ2*      (2,8) = 8.318                      [\*](#TF3){ref-type="table-fn"}**0.011**
              One-way ANOVA                                          *δ:γ2*    (2,8) = 0.165                      0.850
              Independent samples *t* test   Zeitgeber phase         *δ*                        \(10\) = −2.081   **0.064**
              Independent samples *t* test   (light vs dark)         *γ2*                       \(9\) = −3.444    [\*](#TF3){ref-type="table-fn"}**0.007**
              Independent samples *t* test                           *δ:γ2*                     \(9\) = 0.449     0.664
  DD          One-way ANOVA                  Circadian time          *δ*       (2,12) = 0.849                     0.452
              One-way ANOVA                  (CT6 vs CT13 vs CT19)   *γ2*      (2,12) = 7.754                     [\*](#TF3){ref-type="table-fn"}**0.011**
              One-way ANOVA                                          *δ:γ2*    (2,9) = 0.976                      0.413
              Independent samples *t* test   Circadian phase         *δ*                        \(10\) = −0.085   0.933
              Independent samples *t* test   (inactive vs active)    *γ2*                       \(10\) = 4.069    [\*](#TF3){ref-type="table-fn"}**0.002**
              Independent samples *t* test                           *δ:γ2*                     \(10\) = −1.219   0.251

*p* \< 0.05.

![Rhythmic GABA~A~R subunit protein-IR in the SCN. Protein-IR of the synaptic GABA~A~γ2 receptor varied by circadian phase and CT in a 14:10 LD cycle (***B***), with the highest amount of protein-IR during the night (ZT13 and ZT19; active phase). However, after 10 d of free running in DD conditions, the rhythm of synaptic GABA~A~γ2 protein-IR was inverted with highest levels of protein-IR found during the subjective day (CT6, inactive phase; ***E***). The extrasynaptic GABA~A~δ receptor protein-IR did not vary by time of day or phase in either LD or DD conditions (***A***, ***D***). The ratio of δ-IR:γ2-IR did not significantly vary in the whole SCN in either LD or DD (***C***, ***F***). \**p* ≤ 0.05 active versus inactive phase; \#*p* ≤ 0.05 ANOVA. Statistics in [Table 3](#T3){ref-type="table"}.](enu0021723000004){#F4}

Next, to determine whether there were phase-specific effects of lighting condition on protein-IR, we analyzed the SCN for both proteins of interest using a 2 × 2 MANOVA with grayscale value as the dependent variable and circadian phase (active vs inactive phase; i.e., ZT13, ZT19, CT13, CT19 vs ZT6, CT6) and lighting condition (LD vs DD) as independent variables. Grayscale values from the animal's active phase represented the average of IR intensities across active time points, e.g., ZT13, ZT19, CT13, CT19, and inactive phase values were averages of IR intensities from ZT6 and CT6. We further analyzed the relationships between GABA~A~δ and GABA~A~γ2 subunit protein-IR by dividing the SCN into four regions along the rostral-caudal axis ([@B34]; [@B26]), and into dorsal and ventral regions ([@B39]; [@B61]) as described in Materials and Methods. Statistics for this analysis are found in [Table 4](#T4){ref-type="table"}. There was a main effect for lighting condition; differences in both GABA~A~δ and GABA~A~γ2 protein-IR were observed between groups housed in LD versus DD in most subregions of the SCN with higher protein-IR in hamsters housed in DD ([Fig. 5*A--F*](#F5){ref-type="fig"}). In contrast to the effects of lighting condition, there was no main effect for circadian phase; no differences in GABA~A~δ and GABA~A~γ2 protein-IR were observed in any of the subregions between the light and dark phase in hamsters housed in LD cycles or between the subjective day and night in hamsters housed in DD ([Fig. 5*A--F*](#F5){ref-type="fig"}). No interactions were observed between lighting condition and circadian phase in the extrasynaptic GABA~A~δ protein-IR in any SCN subregion (*p* \> 0.05 for all regions; [Fig. 5*A--C*](#F5){ref-type="fig"}). However, there was an interaction between lighting condition and phase in GABA~A~γ2 protein-IR across the whole SCN and in all subregions, with the exception of the rostral SCN (*p* ≤ 0.05; [Fig. 5*D--F*](#F5){ref-type="fig"}). Interestingly, an interaction in the ratio of GABA~A~δ:GABA~A~γ2 protein-IR between lighting condition and circadian phase was observed only in the central posterior SCN subregion (*F*~(1,1)~ = 4.72, *p* ≤ 0.05; [Fig. 5*G*](#F5){ref-type="fig"}), which is the retinorecipient region in Syrian hamsters ([@B34]; [Fig. 3*A*](#F3){ref-type="fig"}). Further analysis revealed that this interaction in the ratio of GABA~A~δ:GABA~A~γ2 protein-IR between lighting condition and circadian phase was significant in the dorsal central posterior subregion (*F*~(1,1)~ = 4.81, *p* ≤ 0.05; [Fig. 5*H*](#F5){ref-type="fig"}), and nearly reached significance in the ventral central posterior subregion (*F*~(1,1)~ = 4.13, *p* = 0.056; [Fig. 5*I*](#F5){ref-type="fig"}).

###### 

MANOVA of GABA~A~R protein-IR in the SCN by region

  SCN region                           GABA~A~δ                          GABAAγ2                 GABA~A~δ:GABAAγ2          
  --------------------------- -------- ---------- ------------- -------- --------- ------------- ------------------ ------ -------------
  Whole                                                                                                                    
      Phase                   83.68    1.78       0.196         11.78    1.28      0.271         0.01               0.62   0.442
      Light cycle             323.91   6.88       **\*0.015**   126.77   13.81     **\*0.001**   0.01               0.47   0.501
      Phase × light cycle     68.48    1.45       0.240         235.19   25.62     **\*0.000**   0.02               1.56   0.226
  Dorsal                                                                                                                   
      Phase                   73.46    1.51       0.231         7.20     0.56      0.465         0.01               0.68   0.421
      Light cycle             272.70   5.61       **\*0.027**   99.44    7.67      **\*0.012**   0.01               0.43   0.518
      Phase × light cycle     55.82    1.15       0.295         228.06   17.59     **\*0.000**   0.02               1.67   0.212
  Ventral                                                                                                                  
      Phase                   106.46   2.30       0.143         23.07    3.51      0.077         0.01               0.52   0.479
      Light cycle             426.95   9.23       **\*0.006**   185.34   28.19     **\*0.000**   0.01               0.51   0.483
      Phase × light cycle     95.68    2.07       0.164         248.53   37.80     **\*0.000**   0.02               1.56   0.226
  Rostral                                                                                                                  
      Phase                   122.54   2.68       0.115         5.76     0.16      0.690         0.02               1.32   0.265
      Light cycle             287.92   6.30       **\*0.020**   55.32    1.58      0.224         0.02               1.31   0.267
      Phase × light cycle     72.96    1.60       0.219         116.86   3.33      0.084         0.01               0.44   0.516
  Central anterior                                                                                                         
      Phase                   86.75    1.68       0.208         0.00     0.00      0.997         0.01               0.61   0.446
      Light cycle             209.11   4.05       **0.056**     235.51   15.56     **\*0.001**   0.00               0.03   0.855
      Phase × light cycle     41.01    0.79       0.382         160.48   10.60     **\*0.004**   0.01               0.46   0.505
  Central posterior                                                                                                        
      Phase                   65.06    1.16       0.292         17.33    0.98      0.335         0.00               0.14   0.710
      Light cycle             351.60   6.28       **\*0.020**   260.17   14.67     **\*0.001**   0.00               0.01   0.930
      Phase × light cycle     97.42    1.74       0.200         581.64   32.80     **\*0.000**   0.06               4.72   **\*0.043**
  Caudal                                                                                                                   
      Phase                   66.28    1.13       0.298         51.62    2.71      0.116         0.00               0.13   0.718
      Light cycle             475.70   8.12       **\*0.009**   37.50    1.97      0.177         0.04               2.40   0.138
      Phase × light cycle     68.66    1.17       0.290         189.02   9.92      **\*0.005**   0.02               0.86   0.366
  Dorsal rostral                                                                                                           
      Phase                   112.46   2.64       0.118         7.90     0.20      0.664         0.02               1.13   0.302
      Light cycle             231.78   5.45       **\*0.029**   45.00    1.11      0.305         0.02               1.13   0.300
      Phase × light cycle     58.72    1.38       **\*0.252**   120.19   2.97      0.101         0.01               0.61   0.444
  Dorsal central anterior                                                                                                  
      Phase                   67.67    1.33       0.261         3.17     0.20      0.661         0.02               0.85   0.368
      Light cycle             161.21   3.16       0.089         233.85   14.66     **\*0.001**   0.00               0.14   0.710
      Phase × light cycle     33.37    0.65       0.427         111.93   7.02      **\*0.016**   0.01               0.29   0.595
  Dorsal central posterior                                                                                                 
      Phase                   67.79    1.14       0.297         6.02     0.28      0.605         0.01               0.45   0.512
      Light cycle             306.71   5.15       **\*0.033**   181.46   8.36      **\*0.009**   0.00               0.01   0.930
      Phase × light cycle     82.33    1.38       0.252         554.05   25.52     **\*0.000**   0.06               4.81   **\*0.041**
  Dorsal caudal                                                                                                            
      Phase                   52.12    0.76       0.392         52.56    2.02      0.171         0.00               0.09   0.772
      Light cycle             425.19   6.21       **\*0.020**   19.51    0.75      0.397         0.05               2.05   0.169
      Phase × light cycle     54.35    0.79       0.382         234.85   9.04      **\*0.007**   0.03               1.28   0.273
  Ventral rostral                                                                                                          
      Phase                   146.81   2.63       0.119         2.72     0.09      0.768         0.03               1.67   0.212
      Light cycle             402.46   7.20       **\*0.013**   76.96    2.53      0.128         0.03               1.45   0.243
      Phase × light cycle     102.11   1.83       0.190         110.90   3.64      0.072         0.00               0.17   0.687
  Ventral central anterior                                                                                                 
      Phase                   132.25   2.23       0.149         10.31    0.48      0.496         0.01               0.28   0.603
      Light cycle             308.83   5.20       **\*0.032**   238.55   11.16     **\*0.003**   0.00               0.02   0.885
      Phase × light cycle     56.96    0.96       0.338         271.83   12.71     **\*0.002**   0.01               0.80   0.384
  Ventral central posterior                                                                                                
      Phase                   59.39    1.06       0.313         53.12    2.53      0.128         0.00               0.01   0.908
      Light cycle             436.59   7.81       **\*0.010**   440.73   21.00     **\*0.000**   0.00               0.16   0.698
      Phase × light cycle     130.97   2.34       0.140         633.84   30.20     **\*0.000**   0.05               4.13   **0.056**
  Ventral caudal                                                                                                           
      Phase                   98.98    2.22       0.150         49.92    3.90      0.063         0.00               0.34   0.569
      Light cycle             581.86   13.07      **\*0.001**   85.46    6.68      **\*0.018**   0.04               3.19   0.090
      Phase × light cycle     100.62   2.26       0.146         118.04   9.22      **\*0.007**   0.00               0.12   0.736

![Interaction between lighting condition and circadian phase in GABA~A~R protein-IR in whole SCN and the dorsal and ventral subdivisions of the SCN. Lighting condition (LD vs DD) had a main effect on both extrasynaptic GABA~A~δ (***A--C***) and synaptic GABA~A~γ2 (***D--F***) protein-IR. There were no main effects of circadian phase (active phase vs inactive phase) on the protein-IR of either subunit. Lighting condition and circadian phase did not interact to affect protein-IR of extrasynaptic GABA~A~δ protein (***A--C***). There was an interaction of lighting condition and circadian phase in the protein-IR of synaptic GABA~A~γ2 receptors across the whole SCN and in all subdivisions, with the exception of the rostral SCN (***D--F***). Lighting condition and circadian phase interacted to affect the ratio of mean protein-IR of extrasynaptic GABA~A~δ to synaptic GABA~A~γ2 in the retinorecipient (central posterior) region of the SCN (***G***), where extrasynaptic receptor protein-IR was relatively higher during the subjective night and synaptic receptor protein-IR was relatively higher during the subjective day. This effect was significant in the dorsal central posterior SCN (***H***) and almost reached significance in the ventral central posterior SCN (***I***). \**p* ≤ 0.05 LD versus DD, \#*p* ≤ 0.05 for interaction between lighting regimen and circadian phase. Statistics in [Table 4](#T4){ref-type="table"}.](enu0021723000005){#F5}

Given that we found a significant main effect of environmental lighting condition on protein-IR, we next analyzed our data to determine whether differences existed in protein-IR between LD and DD conditions. Protein-IR values, by SCN subdivision, were averaged across the day for animals in each lighting condition (i.e., LD: average of ZT6, ZT13, and ZT19; DD: average of CT6, 13, and 19), and then analyzed for effects of lighting condition (LD vs DD) by independent samples *t* test ([Table 5](#T5){ref-type="table"}). GABA~A~δ-IR was greater in DD than LD in many subregions of the SCN ([Fig. 6](#F6){ref-type="fig"}), although the effects failed to reach statistical significance in several of the dorsal subregions and one of the ventral subregions ([Fig. 6*B*,*C*](#F6){ref-type="fig"}). The effects of environmental light cycles were not as robust on GABA~A~γ2-IR, however, protein-IR levels were higher in DD in the central anterior region in the whole SCN and the dorsal SCN ([Fig. 6*D*](#F6){ref-type="fig"}) as well as in the central anterior ([Fig. 6*E*,*F*](#F6){ref-type="fig"}) and posterior ventral SCN ([Fig. 6*F*](#F6){ref-type="fig"}).

###### 

Independent samples *t* test comparing GABA~A~R protein-IR in regions of the SCN between LD and DD

  Protein   SCN region                  *t* value         *p* value
  --------- --------------------------- ----------------- ------------------------------------------
  δ         Whole SCN                   \(25\) = −2.314   [\*](#TF4){ref-type="table-fn"}**0.029**
            Rostral                     \(25\) = −2.137   [\*](#TF4){ref-type="table-fn"}**0.043**
            Central anterior            \(25\) = −1.810   **0.082**
            Central posterior           \(25\) = −2.165   [\*](#TF4){ref-type="table-fn"}**0.040**
            Caudal                      \(25\) = −2.636   [\*](#TF4){ref-type="table-fn"}**0.014**
  γ2        Whole SCN                   \(21\) = −1.544   0.142
            Rostral                     \(24\) = −0.806   0.428
            Central anterior            \(24\) = −2.761   [\*](#TF4){ref-type="table-fn"}**0.011**
            Central posterior           \(23\) = −1.582   0.127
            Caudal                      \(22\) = −0.690   0.497
  δ         Dorsal whole SCN            \(25\) = −2.117   [\*](#TF4){ref-type="table-fn"}**0.044**
            Dorsal rostral              \(25\) = −1.996   **0.057**
            Dorsal central anterior     \(25\) = −1.606   0.121
            Dorsal central posterior    \(25\) = −1.981   **0.059**
            Dorsal caudal               \(25\) = −2.356   [\*](#TF4){ref-type="table-fn"}**0.027**
  γ2        Dorsal whole SCN            \(21\) = −1.203   0.242
            Dorsal rostral              \(24\) = −0.672   0.508
            Dorsal central anterior     \(24\) = −2.799   [\*](#TF4){ref-type="table-fn"}**0.010**
            Dorsal central posterior    \(23\) = −1.160   0.258
            Dorsal caudal               \(22\) = −0.239   0.813
  δ         Ventral whole SCN           \(25\) = −2.615   [\*](#TF4){ref-type="table-fn"}**0.015**
            Ventral rostral             \(25\) = −2.277   [\*](#TF4){ref-type="table-fn"}**0.032**
            Ventral central anterior    \(25\) = −2.036   **0.052**
            Ventral central posterior   \(25\) = −2.371   [\*](#TF4){ref-type="table-fn"}**0.026**
            Ventral caudal              \(25\) = −3.176   [\*](#TF4){ref-type="table-fn"}**0.004**
  γ2        Ventral whole SCN           \(21\) = −2.178   [\*](#TF4){ref-type="table-fn"}**0.041**
            Ventral rostral             \(24\) = −1.022   0.317
            Ventral central anterior    \(24\) = −2.283   [\*](#TF4){ref-type="table-fn"}**0.032**
            Ventral central posterior   \(23\) = −2.146   [\*](#TF4){ref-type="table-fn"}**0.043**
            Ventral caudal              \(22\) = −1.745   0.095

*p* \< 0.05.

![The SCN of hamsters housed in DD for 10 d had higher GABA~A~R subunit protein-IR than found in the SCN of those housed in LD (***A***, ***D***). The effects of housing in DD were more robust in the ventral SCN (***C***, ***F***) than the dorsal SCN (***B***, ***E***). Overall, protein-IR levels were calculated by averaging across the three sampling time points for each housing condition. \**p* ≤ 0.05 LD versus DD. Statistics in [Table 5](#T5){ref-type="table"}.](enu0021723000006){#F6}

As discussed above the dorsal and ventral SCN have been shown to have different roles in entrainment (reviewed in [@B39]; [@B33]; [@B61]; [@B2]), thus we then analyzed our data to identify differences in GABA~A~R-IR between the dorsal and ventral SCN using an independent samples *t* test. The results of this analysis are found in [Figure 7](#F7){ref-type="fig"} and [Table 6](#T6){ref-type="table"}. We found no differences in GABA~A~δ protein-IR levels between the dorsal and ventral SCN at any time point in LD or DD ([Fig. 7*A--F*](#F7){ref-type="fig"}). Compared with the dorsal region, the ventral SCN had higher levels of GABA~A~γ2 protein-IR late in the active phase ([Fig. 7*I*,*L*](#F7){ref-type="fig"}). This effect was driven by higher protein-IR in the ventral central anterior region during the night in LD (ZT19; [Fig. 7*I*](#F7){ref-type="fig"}) and by higher protein-IR in the ventral central posterior region during the subjective night in DD (CT19; [Fig. 7*L*](#F7){ref-type="fig"}).

![GABA~A~-TONIC receptor protein-IR did not vary between the dorsal and ventral SCN at any time point in either LD or DD (***A--F***). In the central anterior region, GABA~A~-PHASIC receptor protein-IR (***G--L***) was higher in the ventral SCN compared with the dorsal SCN at ZT19 (***I***). At CT19 GABA~A~-PHASIC receptor protein-IR was higher in the ventral SCN compared with the dorsal SCN across the whole SCN (***L***). This effect was strongest in the central posterior and caudal SCN. \**p* ≤ 0.05. Statistics in [Table 6](#T6){ref-type="table"}.](enu0021723000007){#F7}

###### 

Comparison of GABA~A~R protein-IR between dorsal and ventral SCN by time point

  Protein   Time point   SCN region          *t* value        *p* value
  --------- ------------ ------------------- ---------------- --------------------------------------------
  δ         ZT6          Whole SCN           \(6\) = −0.066   0.095
                         Rostral             \(6\) = −0.152   0.884
                         Central anterior    \(6\) = −0.139   0.896
                         Central posterior   \(6\) = −0.381   0.716
                         Caudal              \(6\) = 0.692    0.515
  δ         ZT13         Whole SCN           \(6\) = −0.398   0.704
                         Rostral             \(6\) = −0.489   0.642
                         Central anterior    \(6\) = −0.743   0.486
                         Central posterior   \(6\) = −0.197   0.850
                         Caudal              \(6\) = −0.111   0.915
  δ         ZT19         Whole SCN           \(6\) = −0.443   0.673
                         Rostral             \(6\) = −0.370   0.724
                         Central anterior    \(6\) = −0.506   0.631
                         Central posterior   \(6\) = −0.656   0.536
                         Caudal              \(6\) = −0.172   0.869
  δ         CT6          Whole SCN           \(8\) = −0.758   0.470
                         Rostral             \(8\) = −0.948   0.371
                         Central anterior    \(8\) = −0.660   0.528
                         Central posterior   \(8\) = −0.930   0.380
                         Caudal              \(8\) = −0.270   0.794
  δ         CT13         Whole SCN           \(8\) = −0.210   0.839
                         Rostral             \(8\) = −0.205   0.843
                         Central anterior    \(8\) = −0.363   0.726
                         Central posterior   \(8\) = −0.206   0.842
                         Caudal              \(8\) = −0.082   0.937
  δ         CT19         Whole SCN           \(6\) = −0.642   0.545
                         Rostral             \(6\) = −0.642   0.544
                         Central anterior    \(6\) = −0.875   0.415
                         Central posterior   \(6\) = −0.712   0.503
                         Caudal              \(6\) = −0.236   0.821
  γ2        ZT6          Whole SCN           \(6\) = 0.162    0.877
                         Rostral             \(6\) = 0.347    0.741
                         Central anterior    \(6\) = 0.125    0.905
                         Central posterior   \(6\) = −0.145   0.889
                         Caudal              \(6\) = 0.197    0.850
  γ2        ZT13         Whole SCN           \(6\) = 0.127    0.903
                         Rostral             \(6\) = 0.623    0.556
                         Central anterior    \(6\) = −1.115   0.308
                         Central posterior   \(6\) = −0.368   0.726
                         Caudal              \(6\) = 0.910    0.413
  γ2        ZT19         Whole SCN           \(4\) = −1.076   0.343
                         Rostral             \(6\) = 0.034    0.974
                         Central anterior    \(6\) = −4.497   [^\*^](#TF5){ref-type="table-fn"}**0.004**
                         Central posterior   \(6\) = −1.240   0.261
                         Caudal              \(4\) = 0.106    0.156
  γ2        CT6          Whole SCN           \(6\) = −0.931   0.388
                         Rostral             \(8\) = 0.041    0.969
                         Central anterior    \(8\) = −1.151   0.283
                         Central posterior   \(6\) = −1.796   0.123
                         Caudal              \(8\) = 0.018    0.986
  γ2        CT13         Whole SCN           \(6\) = −0.217   0.836
                         Rostral             \(8\) = 0.347    0.738
                         Central anterior    \(8\) = −0.519   0.618
                         Central posterior   \(8\) = −1.708   0.127
                         Caudal              \(6\) = 0.085    0.935
  γ2        CT19         Whole SCN           \(6\) = −2.620   [^\*^](#TF5){ref-type="table-fn"}**0.040**
                         Rostral             \(6\) = −0.207   0.843
                         Central anterior    \(6\) = −1.170   0.286
                         Central posterior   \(6\) = −3.037   [^\*^](#TF5){ref-type="table-fn"}**0.023**
                         Caudal              \(6\) = −2.514   [^\*^](#TF5){ref-type="table-fn"}**0.046**

*p* \< 0.05.

###### 

Sample sizes

  Experiment   Group                *N*
  ------------ -------------------- -----
  1            CT6 SALINE-NP        7
               CT6 THIP-NP          8
               CT6 MUSCIMOL-NP      9
               CT13.5 SALINE-LP     3
               CT13.5 THIP-LP       6
               CT13.5 MUSCIMOL-LP   5
               CT13.5 THIP-NP       3
               CT13.5 MUSCIMOL-NP   4
               CT19 SALINE-LP       6
               CT19 THIP-LP         4
               CT19 MUSCIMOL-LP     5
               CT19 THIP-NP         3
               CT19 MUSCIMOL-NP     4
  2            CT6                  5
               CT13.5               5
               CT19                 6
               ZT6                  6
               ZT13.5               6
               ZT19                 5
  3            CT6                  5
               CT13.5               5
               CT19                 5
               ZT6                  4
               ZT13.5               4
               ZT19                 4

Discussion {#s5}
==========

The different temporal patterns in the expression of δ and γ2 subunit mRNA and protein-IR observed across all subregions of the SCN suggests that GABA~A~-TONIC extrasynaptic receptors and GABA~A~-PHASIC synaptic receptors are differentially regulated within the SCN. Interestingly, while δ protein-IR levels did not significantly change across the circadian cycle, γ2 protein-IR displayed significant rhythmicity in the SCN of hamsters housed in LD and DD. Comparison of the relative changes in γ2 protein-IR in hamsters housed in LD and DD suggests that this protein may be regulated by the circadian pacemaker as well as by environmental light. In hamsters housed in DD, the relative amounts of γ2 protein-IR varied significantly over the circadian cycle with peak levels occurring during the subjective day ([Fig. 4*E*](#F4){ref-type="fig"}). In hamsters housed in LD, the amounts of γ2 protein-IR also varied significantly, however, the lowest levels of γ2 protein-IR were observed during light phase ([Fig. 4*B*](#F4){ref-type="fig"}) suggesting that environmental light inhibits γ2 protein levels. The possibility that δ protein levels are also inhibited by light cannot be excluded because the lower levels of this protein-IR seen during the light phase in LD approached but did not reach statistical significance ([Fig. 4*A*](#F4){ref-type="fig"}). Additionally, hamsters housed in LD, compared with those housed in DD, had reduced protein-IR for both subunits, and this effect was strongest in the ventral SCN ([Fig. 6](#F6){ref-type="fig"}). Taken together, these data suggest that when analyzed across the entire SCN GABA~A~Rs containing the δ subunit (i.e., extrasynaptic GABA~A~-TONIC receptors) remain relatively constant across time whereas GABA~A~Rs containing the γ2 subunit (i.e., synaptic GABA~A~-PHASIC receptors) are regulated by the circadian pacemaker, and both receptor subtypes may be influenced by environmental lighting conditions. Of course, the presence of GABA~A~R subunits alone does not indicate the presence of functional receptors ([@B48]), so direct measures of tonic and phasic currents within neurons of the SCN across the circadian cycle will be necessary to further support this possibility.

Despite the significant temporal variations in γ2 protein-IR in the SCN of hamsters housed in DD and LD the ratio of the mean protein-IR levels of δ-to-γ2 did not change significantly when analyzed across all subdivisions of the nucleus. In contrast, however, the ratio of δ-to-γ2 protein-IR was found to change significantly across the circadian cycle in a region-specific manner. Specifically, the ratio of δ-to-γ2 protein-IR was significantly greater during the night than during the day but only in the subregion of the SCN that corresponds to the retinorecipient area of the nucleus ([Fig. 5](#F5){ref-type="fig"}). These data suggest that within the discrete region of the SCN that is innervated by direct projections from the retina, the δ subunit containing extrasynaptic GABA~A~-TONIC receptors may play a larger role in mediating the response to GABA than the γ2 containing synaptic GABA~A~-PHASIC receptors during the night, while the opposite is true during the day. If GABA~A~Rs in the retinorecipient region of the SCN mediate the ability of GABA to alter circadian phase, then GABA agonists that act selectively on extrasynaptic GABA~A~-TONIC receptors would be predicted to be more efficacious in modulating phase shifts during the night while agonists that act selectively on synaptic GABA~A~-PHASIC receptors would be predicted to be more effective during the day. The data from experiment 1, along with previous work ([@B15]; [@B36]), support this hypothesis. Injection of THIP, an extrasynaptic δ superagonist, inhibits the phase shifting effects of light at night but has no effect on circadian phase during the day, and diazepam, a benzodiazepine that acts on γ2 subunit containing GABA~A~Rs, phase shifts circadian rhythms during the day but does not influence circadian phase at night. Further, muscimol, which activates both extrasynaptic and synaptic GABA~A~Rs, influences circadian phase during both the day and night. These studies, however, should be interpreted with caution because the pharmacological actions of these drugs can be complicated (for a review, see [@B2]), and there may be differences in processes downstream from GABA~A~ signaling in the SCN which also influence the behavioral responses to GABA~A~R activation across the circadian cycle. Nevertheless, the significant increase in the ratio of δ-to-γ2 receptor protein-IR within the retinorecipient region of the SCN during the subjective night could indicate a shift in the balance of GABA's effects from synaptic phasic modulation during the subjective day to extrasynaptic tonic modulation during the subjective night.

Other recent data also suggest that rhythms in the balance of tonic versus phasic GABA~A~-induced conductance may be important in determining the phase of the circadian pacemaker. It has recently been demonstrated that the *sustained* activation of GABA~A~Rs in the SCN (\>4 h) is both necessary and sufficient for the induction of phase delays by light ([@B29]). Interestingly, recent SCN modeling studies predict that sustained tonic GABA signaling, but not a sustained phasic GABA signaling, can phase shift the molecular pacemaker ([@B13]). These data combined with the present findings that the ratio of tonic:phasic GABA~A~Rs may be highest during the subjective night within the retinorecipient subregion of the nucleus suggest the hypothesis that the sustained effects of GABA on phase resetting at night may be mediated by extrasynaptic GABA~A~-TONIC receptors. Thus, a sustained tonic GABA signal may necessarily need to be transduced through a nondesensitizing receptor, such as the extrasynaptic GABA~A~-TONIC receptor. Additional experiments will be necessary to determine which GABA~A~R subtype mediates the sustained effects of GABA on photic phase shifts, or whether both tonic and phasic receptors play a role in this intriguing process.

Data on GABA~A~R mRNA expression in the SCN are sparse in the literature. Using Northern blottings in extracts of the SCN from mice, transcripts were found for α~1,2,3,4,5~, β~1,2,3~, and γ~1,2~ subunits, however, transcripts for the δ and ρ subunits were not detected ([@B47]). Using microarray technology, transcripts for all 19 currently identified GABA~A~R subunits were found in the SCN of mice (Mouse 1.OST SCN 2014; [@B53]). It is interesting to note that within this same database in another dataset (mouse wild-type SCN, GNF Microarray), there was a diurnal rhythm in γ2 mRNA expression in the SCN of wild-type mice, with peak expression at night and nadir during the day. Interestingly, this expression pattern was antiphase in *clock* mutants with γ2 mRNA peak expression occurring during the day ([@B53]), suggesting that transcription of γ2 may be under control of one of the genes comprising the molecular circadian pacemaker (i.e., *clock*).

Studies on GABA~A~ subunit protein expression in the SCN are also quite limited. Gao and colleagues investigated the protein expression of six different GABA~A~R subunits in the SCN of rats and found that IR was robust for α~2~, α~3~, α~5~, and γ~2~, but no staining was detected for α~1~ and β~2/3~ ([@B22]). However, this neuroanatomical study did not indicate the time of day the tissues were collected. Given that GABA~A~R subunit protein can vary considerably across the circadian cycle ([Fig. 3](#F3){ref-type="fig"}; [@B45]), it is possible that the lack of IR reported for α~1~ and β~2/3~ was an artifact of time of day the tissues were collected. Indeed, both α~1~ and β~2/3~ mRNA expression has been reported in the SCN ([@B47]; [@B53]), as well as β~3~ protein ([@B45]; [@B4]). To our knowledge, only one previous study has directly investigated temporal patterns of GABA~A~R protein expression in the SCN. Of the four subunits examined (α~2~, α~5~, β~1~, β~3~), only β~1~ was found to vary across the circadian cycle, with more protein at night (ZT16 and CT16) than during the day (ZT4 and CT4; [@B45]). Given that tissues were collected after only 2 d in DD, it is not clear whether this is a true circadian rhythm or a damped rhythm following exposure to the 14:10 LD cycle. As noted earlier, the presence of GABA~A~ subunits does not necessarily demonstrate the existence of functional GABA~A~Rs containing those subunits (reviewed in [@B48]). A pharmacological study of Zn^2+^-mediated GABA~A~R inhibition found greater inhibition of GABA-induced current during the day than at night in the SCN of rats housed in standard LD conditions ([@B32]). Given that GABA~A~Rs with a γ subunit are insensitive to Zn^2+^ inhibition, the authors concluded that the proportion of γ subunit containing receptors in the SCN was higher at night than during the day, which is consistent with our current findings in the SCN of hamsters housed in LD ([Figs. 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}).

Our current findings that protein-IR patterns for GABA~A~Rs in the SCN are different from the expression patterns of their genes ([Figs. 2](#F2){ref-type="fig"}, [4](#F4){ref-type="fig"}) is a phenomenon that has also been reported in other studies (described below) on transcript-protein expression relationships in the SCN. Peroxisome proliferator-activated receptor β/δ mRNA and protein display rhythmicity in the SCN of animals housed in LD cycles, but in DD, mRNA expression remains rhythmic whereas protein expression does not ([@B9]). Further evidence that transcript and protein rhythms can be uncoupled comes from a recent SCN proteome study that analyzed 2112 proteins. This study concluded that "transcript levels are a poor predictor of protein abundance" based on the finding that among 421 transcripts which were expressed in a 24 h pattern, only nine of the proteins corresponding to those transcripts were rhythmically expressed ([@B10]). Taken together, these findings suggest that the circadian protein rhythms of GABA~A~Rs subunits and their ratios in the SCN are more likely to be regulated by posttranscriptional factors than by transcriptional rhythms.

How might rhythms in protein expression and relative ratios of proteins develop independent of rhythms (or lack thereof) in transcripts? One possibility is that homeostatic reciprocal regulation between GABA~A~δ and GABA~A~γ2 proteins may affect their expression in a seesaw manner ([@B31]; [@B60]), resulting in the different effects of tonic and phasic GABA~A~ agonists across the circadian cycle in the SCN. This mechanistically simple hypothesis does not appear to be supported by our data across the whole SCN, as changes in GABA~A~γ2 protein-IR are not accompanied by significant and reciprocal changes in GABA~A~δ protein-IR ([Fig. 4](#F4){ref-type="fig"}). Indeed, lighting conditions (LD vs DD) appear to have a greater influence on the expression of GABA~A~Rs than homeostatic competition driven by their relative abundance ([Figs. 4](#F4){ref-type="fig"}--[6](#F6){ref-type="fig"}). The interaction of light and circadian phase on GABA~A~R ratio in the retinorecipient SCN ([Fig. 5*G--I*](#F5){ref-type="fig"}) does suggest that protein expression in this area may be differentially regulated than in other SCN regions. Thus, it may be possible that homeostatic reciprocal regulation between GABA~A~δ and GABA~A~γ2 protein may indeed occur in the retinorecipient SCN.

In conclusion, circadian rhythms in the ratio of δ-to-γ2 GABA~A~R-IR in the retinorecipient SCN may mediate the phase-dependent effects of GABA on the circadian pacemaker. Within the circadian pacemaker, patterns of GABA~A~R transcript expression do not predict patterns of protein expression, and light appears to have a greater influence on GABA~A~R protein expression than does circadian transcriptional regulation. Although the effects of environmental light on GABA~A~R protein-IR are apparent across the entire SCN, the retinorecipient area is differentially affected. These findings provide insight into the complex effects of GABA in the SCN across the circadian cycle and highlight the need for future studies to identify the exact subunit composition, anatomic distribution, temporal patterns of expression, and regulatory factors influencing the expression and function of GABA~A~Rs in the circadian pacemaker.
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As previously noted, the research indicates that two GABA(A) receptor subunits are expressed throughout the suprachiasmatic nucleus. The data also suggest that there is a small rhythm in the expression of the subunits that might contribute to different roles for synaptic and extrasynaptic GABA(A) receptors in the SCN. The authors have been responsive to prior reviews, and at this point some small revisions are suggested. These will be reviewed by the editor (only).

The manuscript tends to overstate the significance of the data, given that the rhythms shown, while statistically significant, are small relative to the total protein/mRNA levels. This can be clarified by changing the visual abstract to reflect a less dramatic day/night difference in the abundance of the two subunits. The significance statement and abstract discuss these differences as a change in balance, which is well put and more accurate. Also, the discussion might state directly that combining the two nighttime data sets and comparing them to the daytime reflects a functional grouping and is reasonable, and that it was necessary because of the subtle rhythms being measured. That said, given that the effects are subtle, this may suggest that the role of the two populations of receptors in the behavioral responses is more related to their downstream signaling (among other possible mechanisms) than to changes in their expression pattern?

Please address these comments; the changes will be reviewed by the editor only.
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